Tag: TME

The Role of Nanoparticles in Cancer Therapy: Advancements in Nanotechnology

With the advent and advancements in nanotechnology, the field of cancer therapy is witnessing a paradigm shift. Nanoparticles, owing to their unique properties, are proving to be promising carriers for drug delivery in cancer therapy. The study scrutinizes the transport of nanoparticles in two abnormal microenvironments through a 2-D simulation…

Continue Reading The Role of Nanoparticles in Cancer Therapy: Advancements in Nanotechnology

Bioinformatics-based analysis of the relationship between disulfidptosis and prognosis and treatment response in pancreatic cancer

Identification of DRGs in PCa Figure 1a showed the flow chart of this study. To explore the role of DRGs in PCa, we analyzed the gene expression profiles of these 15 DRGs in PCa patients. As shown in Fig. 1b, for ACTN4, TLN1, IQGAP1, CD2AP, FLNA, MYH9, MYL6, and ACTB genes, the…

Continue Reading Bioinformatics-based analysis of the relationship between disulfidptosis and prognosis and treatment response in pancreatic cancer

Morphogenesis, Inc. Announces Corporate Rebranding to TuHURA Biosciences, Inc. and Provides a Business Overview

Company focused on advancing novel personalized cancer vaccines to overcome tumor resistance to immunotherapies like checkpoint inhibitors; and first-in-class bi-functional antibody drug conjugates (ADCs) targeting Myeloid Derived Suppressor Cells (MDSCs) to modulate their immunosuppressive effects on the tumor microenvironment Company on track to initiate pivotal Phase 3 study of lead…

Continue Reading Morphogenesis, Inc. Announces Corporate Rebranding to TuHURA Biosciences, Inc. and Provides a Business Overview

CHEK2 is a potential prognostic biomarker associated with immune infiltration in clear cell renal cell carcinoma

CHEK2 expression increased in cancer tissues First, the expression levels of CHEK2 in different tumor types in the TIMER database were evaluated. All tumors except for chromophobe renal cell carcinoma (KICH) showed elevated levels of CHEK2 expression compared to normal cells (Fig. 1A). Similarly, CHEK2 protein expression was upregulated in all…

Continue Reading CHEK2 is a potential prognostic biomarker associated with immune infiltration in clear cell renal cell carcinoma

Senior Technical Marketing Manager at imperva

SENIOR TECHNICAL MARKETING MANAGER CYBER SECURITY is a big deal. It’s in the news, growing rapidly, a critical tool for every company, and our specialty. Imperva is a public company (NASDAQ) and cybersecurity leader that delivers best-in-class solutions to protect data and applications on-premises, in the cloud, and across hybrid…

Continue Reading Senior Technical Marketing Manager at imperva

Scenic Biotech Announces Positive Preclinical Data for its QPCTL Inhibitor SC-2882 as Potential New Therapeutic Approach for Diffuse Large B-Cell Lymphoma

SC-2882 shows anti-lymphoma and anti-immunosuppression effect in a mouse model for diffuse large B-Cell lymphoma Data presented today, December 9, at the 65th ASH Annual Meeting & Exposition in San Diego, CA, by Leandro Cerchietti, MD, Richard A. Stratton Associate Professor in Hematology and Oncology at Weill Cornell Medicine, New…

Continue Reading Scenic Biotech Announces Positive Preclinical Data for its QPCTL Inhibitor SC-2882 as Potential New Therapeutic Approach for Diffuse Large B-Cell Lymphoma

NOTCH1 mutations predict superior outcomes, NSCLC

Introduction Lung cancer remains the leading cause of cancer-related mortality worldwide, and the majority are non-small-cell lung cancer (NSCLC).1,2 Genetic variation is a typical feature of NSCLC that drives cancer initiation and progression.3 Understanding the role of mutated genes in NSCLC is the basis of the development of novel treatment…

Continue Reading NOTCH1 mutations predict superior outcomes, NSCLC

cGAS-STING pathway targeted therapies and their applications in the treatment of high-grade glioma.

cGAS-STING pathway targeted therapies and their applications in the treatment of high-grade glioma. Publication ,  Journal Article Tripathi, S; Najem, H; Mahajan, AS; Zhang, P; Low, JT; Stegh, AH; Curran, MA; Ashley, DM; James, CD; Heimberger, AB Published in: F1000Res Median survival of patients with glioblastoma (GBM) treated with standard of…

Continue Reading cGAS-STING pathway targeted therapies and their applications in the treatment of high-grade glioma.

Vacature Postdoc position in Bioinformatics

In this TKI-PPP funded project, our objective is to construct a comprehensive landscape of the tumor microenvironment in cervical cancer patients and investigate its potential clinical applications using cutting-edge bioinformatic and molecular profili… Cervical cancer ranks fourth leading causes of cancer death in women globally, with approximately 800-900 diagnosis annually…

Continue Reading Vacature Postdoc position in Bioinformatics

Comprehensive Molecular Tumor Analysis (CMTA) integrating RNAseq and tumor immune microenvironment (TME) for targeted therapy (India)

Precision oncology approaches have made great strides harnessing individual tumor mutation profiles to guide targeted therapy choices. However, deeper molecular insights are needed to improve personalized treatment decisions that are tailored to specific molecular characteristics of a tumor. Integrating gene expression analysis in personalized oncology provides an additional level of…

Continue Reading Comprehensive Molecular Tumor Analysis (CMTA) integrating RNAseq and tumor immune microenvironment (TME) for targeted therapy (India)

a promising approach in cancer care

Immunotherapy has revolutionized cancer treatment, offering promising avenues beyond traditional methods. Recent breakthroughs showcased at the Society for Immunotherapy of Cancer’s (SITC) annual meeting have spotlighted innovative approaches, notably chimeric antigen receptor macrophage (CAR-M) therapy, offering new strategies in the fight against solid tumors and addressing the limitations of current…

Continue Reading a promising approach in cancer care

The Evolving Market Dynamics of B-cell Lymphomas: Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, and Burkitt Lymphoma

B-cell lymphoma, a subtype of non-Hodgkin lymphoma, stands as the leading cancer diagnosis in the United States, comprising 85% of all cases. This cancer targets the lymphatic system, encompassing lymph nodes, vessels, and related tissues responsible for fluid transportation within the body. The outlook for B-cell lymphoma patients has been…

Continue Reading The Evolving Market Dynamics of B-cell Lymphomas: Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia, and Burkitt Lymphoma

Breaking through immune suppression with CAR T cells

Since 2017, the United States Food and Drug Administration (FDA) has approved six chimeric antigen receptor (CAR) T cell therapies for treating blood cancers (1). Behind the excitement around these therapies is the concern about patients’ short-lived responses to CAR T cell infusions, limiting their chances of long-term survival. CAR…

Continue Reading Breaking through immune suppression with CAR T cells

[Kernel-packages] [Bug 2007050] Autopkgtest regression report (initramfs-tools/0.142ubuntu15.1)

All autopkgtests for the newly accepted initramfs-tools (0.142ubuntu15.1) for mantic have finished running. The following regressions have been reported in tests triggered by the package: initramfs-tools/0.142ubuntu15.1 (armhf) Please visit the excuses page listed below and investigate the failures, proceeding afterwards as per the StableReleaseUpdates policy regarding autopkgtest regressions [1]. people.canonical.com/~ubuntu-archive/proposed-

Continue Reading [Kernel-packages] [Bug 2007050] Autopkgtest regression report (initramfs-tools/0.142ubuntu15.1)

ncRNA | Free Full-Text | An Overview of the Immune Modulatory Properties of Long Non-Coding RNAs and Their Potential Use as Therapeutic Targets in Cancer

Non-Coding RNA 2023, 9(6), 70; doi.org/10.3390/ncrna9060070 (registering DOI) Non-Coding RNA 2023, 9(6), 70; doi.org/10.3390/ncrna9060070 (registering DOI) Received: 27 June 2023 / Revised: 25 October 2023 / Accepted: 8 November 2023 / Published: 11 November 2023 Round 1 Reviewer 1 Report Comments and Suggestions for Authors In the current manuscript, Moises et al….

Continue Reading ncRNA | Free Full-Text | An Overview of the Immune Modulatory Properties of Long Non-Coding RNAs and Their Potential Use as Therapeutic Targets in Cancer

Tumor microenvironment heterogeneity in bladder cancer identifies biologically distinct subtypes predicting prognosis and anti-PD-L1 responses

Bladder cancer is the most prevalent cancer of the urological system and it is histologically and genomically heterogeneous, which results in highly variable outcomes. Although improved strategies, such as the introduction of Bacillus Calmette-Guerin (BCG) and cisplatin-based chemotherapy, have significantly improved prognosis, that of high-risk, advanced, and metastatic BCa remains…

Continue Reading Tumor microenvironment heterogeneity in bladder cancer identifies biologically distinct subtypes predicting prognosis and anti-PD-L1 responses

BioAtla Reports Third Quarter 2023 Financial Results and Highlights Recent Progress

BioAtla, Inc. Observed additional clinical responses and FDA feedback supports path forward for CAB-AXL-ADC (BA3011) non-small cell lung cancer (NSCLC) registrational study; detailed interim Phase 2 data to be presented at upcoming IASLC conference in early December and discussed at KOL event on December 4, 2023 Observed new PRs with…

Continue Reading BioAtla Reports Third Quarter 2023 Financial Results and Highlights Recent Progress

How to remove outlier from a scatter plot – RStudio IDE

Good Afternoon dear all,Please considering this data, I will like to know the best way to check for outliers in a scatter plot without using the ggplotly function from plotly. Thanks library(tidyverse) library(ggpmisc) library(plotly) library(ggrepel) LeafArea <- tibble::tribble( ~Planting, ~Variety, ~Inoculation, ~Fertilizer, ~Plant, ~leaf, ~mid.lobe.length, ~mid.lobe.width, “May”, “TME 419”, “No”,…

Continue Reading How to remove outlier from a scatter plot – RStudio IDE

Medicenna Presents Preclinical Data on MDNA113, its Targeted Metalloprotease Activated SuperKine (T-MASK) at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Medicenna Therapeutics Corp. Company’s T-MASK platform demonstrates ability to maximize anti-tumor efficacy and minimize systemic toxicity, and opportunities to explore broad range of cytokines and other potent therapeutics MDNA113 is a first-in-class IL-13R⍺2 targeted therapy that delivers a masked bi-specific IL-2-AntiPD1 Superkine to the tumor micro-environment where it is activated…

Continue Reading Medicenna Presents Preclinical Data on MDNA113, its Targeted Metalloprotease Activated SuperKine (T-MASK) at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Medicenna Presents Preclinical Data on MDNA113, its

Company’s T-MASK platform demonstrates ability to maximize anti-tumor efficacy and minimize systemic toxicity, and opportunities to explore broad range of cytokines and other potent therapeutics MDNA113 is a first-in-class IL-13R⍺2 targeted therapy that delivers a masked bi-specific IL-2-AntiPD1 Superkine to the tumor micro-environment where it is activated by cancer specific…

Continue Reading Medicenna Presents Preclinical Data on MDNA113, its

Medicenna Presents Preclinical Data on MDNA113, its Targeted Metalloprotease Activated SuperKine (T-MASK) at the 38th Annual Meeting of the Society for Immunotherapy of Cancer -November 03, 2023 at 12:00 pm EDT

Medicenna Therapeutics Corp. announced new preclinical data demonstrating proof of concept for the Company?s novel T-MASK (Targeted Metallo/protease Activated SuperKine) platform technology with the Company?s development candidate, MDNA113, at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (?SITC?) held in San Diego, CA, from November 1-5, 2023….

Continue Reading Medicenna Presents Preclinical Data on MDNA113, its Targeted Metalloprotease Activated SuperKine (T-MASK) at the 38th Annual Meeting of the Society for Immunotherapy of Cancer -November 03, 2023 at 12:00 pm EDT

Fasting-Mimicking Diet Drives Antitumor Immunity against Colorectal Cancer by Reducing IgA-Producing Cells | Cancer Research

Fasting-mimicking diet (FMD) is emerging as an effective dietary intervention with the potential to prolong life span in healthy people and boost antitumor immunity in patients with cancer. FMD refers to a medically designed fasting-like state that allows periodic consumption of a very-low-calorie and low-protein diet (1, 2). Compared with…

Continue Reading Fasting-Mimicking Diet Drives Antitumor Immunity against Colorectal Cancer by Reducing IgA-Producing Cells | Cancer Research

CRISPR Therapeutics : SITC 2023 (CTX112) -October 31, 2023 at 09:19 am EDT

Title: Development of CTX112 a next generation allogeneic multiplexed CRISPR-edited CART cell therapy with disruptions of the TGFBR2 and Regnase-1 genes for improved manufacturing and potency Authors: Demetrios Kalaitzidis, Mohammed Ghonime, Robert Chain, Nivedita Jaishankar, Davis Settipane, Zinkal Padalia, Lauren Zakas, Meghna Kuppuraju, Paul Tetteh, Mary-LeeDequeant, Sushant Karnik, Chandirasegaran Massilamany,…

Continue Reading CRISPR Therapeutics : SITC 2023 (CTX112) -October 31, 2023 at 09:19 am EDT

Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum eotaxin levels (KG4/2015): an open-label, randomised, Phase 3 trial

Patients This clinical trial was conducted at 16 academic hospitals in Korea, from November 2015 through April 2020. A total of 511 patients underwent a screening test after providing written informed consent (Fig. 1). During the screening, every patient was checked for their serum eotaxin level, where 174 (34.1%) of them…

Continue Reading Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum eotaxin levels (KG4/2015): an open-label, randomised, Phase 3 trial

Construction of a novel prognostic model in skin cutaneous melanoma based on chemokines-related gene signature

Skin cutaneous melanoma, SKCM, is one of the most aggressive treatment-resistant tumours. Despite the fact that the BRAF oncogene and immunological checkpoints such as PD-1/PD-L1 and CTLA-4 have enhanced the therapeutic efficacy of SKCM, the subsequent resistance mechanisms and remedies have raised concerns. Chemokines have a significant role in the…

Continue Reading Construction of a novel prognostic model in skin cutaneous melanoma based on chemokines-related gene signature

Scheduled dosage regimen by irreversible electroporation of loaded erythrocytes for cancer treatment | APL Bioengineering

Stimuli-sensitive drug delivery system (DDS) has attracted tremendous attention due to its ability to allow drug release through a controlled manner in response to endogenous or exogenous stimuli, which can exert site-specific therapeutic effect while minimizing the side effects.1 Extensive efforts have been devoted to explore the ideal DDS capable…

Continue Reading Scheduled dosage regimen by irreversible electroporation of loaded erythrocytes for cancer treatment | APL Bioengineering

PHF5A is a potential diagnostic, prognostic, and immunological biomarker in pan-cancer

PHF5A expression analysis Figure 1A demonstrated that PHF5A expression level was compared between tumor and corresponding normal tissues using TIMER2 tool. As compared to normal tissues, PHF5A expression was considerably elevated in Bladder urothelial carcinoma (BLCA), Breast invasive carcinoma (BRCA), Cholangiocarcinoma (CHOL), Colon adenocarcinoma (COAD), Esophageal carcinoma (ESCA), Head and neck…

Continue Reading PHF5A is a potential diagnostic, prognostic, and immunological biomarker in pan-cancer

STING in tumors: a focus on non-innate immune pathways

The final, formatted version of the article will be published soon. Notify me Receive an email when it is updated You just subscribed to receive the final version of the article Cyclic GMP-AMP synthase (cGAS) and downstream stimulator of interferon genes (STING) are involved in mediating…

Continue Reading STING in tumors: a focus on non-innate immune pathways

Researchers explore immunomodulating targets for improving glioblastoma therapies

In a recent article published in EMBO Molecular Medicine, researchers investigated cellular, molecular, and spatiotemporal heterogeneity of glioblastoma (GBM), a malignant and highly aggressive primary brain tumor. Study: Single-cell profiling and zebrafish avatars reveal LGALS1 as immunomodulating target in glioblastoma. Image Credit: Triff/Shutterstock.com They performed single-cell ribonucleic acid sequencing (scRNA-seq) of…

Continue Reading Researchers explore immunomodulating targets for improving glioblastoma therapies

Identification of lactate regulation pattern on tumor immune infiltration, therapy response, and DNA methylation in diffuse large B-cell lymphoma

Background: Lactate, produced through glycolytic metabolism in the tumor microenvironment (TME), is implicated in tumorigenesis and progression in diverse cancers. However, the impact of lactate on the remodeling of the TME in diffuse large B-cell lymphoma (DLBCL) and its implications for therapy options remain unclear. Method: A lactate-related (LAR) scoring…

Continue Reading Identification of lactate regulation pattern on tumor immune infiltration, therapy response, and DNA methylation in diffuse large B-cell lymphoma

Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas | Acta Neuropathologica Communications

Single-nuclei RNA-sequencing analysis of NF1-associated plexiform neurofibroma reveals specific non-neoplastic and neoplastic cellular subpopulations Single-nuclei RNA-sequencing (snRNA-seq) was performed on 8 bulk frozen PN patient samples capturing approximately 4,000 nuclei per sample, a sufficient number of nuclei to provide adequate coverage to report the high levels of cellular heterogeneity found…

Continue Reading Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas | Acta Neuropathologica Communications

Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas

doi: 10.1186/s40478-023-01639-1. Vladimir Amani  1   2 , Kent A Riemondy  3 , Rui Fu  4 , Andrea M Griesinger  5   6 , Enrique Grimaldo  5   6 , Graziella Ribeiro De Sousa  5   6 , Ahmed Gilani  7 , Molly Hemenway  6 , Nicholas K Foreman  5   6 , Andrew M Donson #  5   6…

Continue Reading Integration of single-nuclei RNA-sequencing, spatial transcriptomics and histochemistry defines the complex microenvironment of NF1-associated plexiform neurofibromas

Characterization of prognosis and immune infiltration by a novel glutamine metabolism-related model in cutaneous melanoma

Open Access ARTICLE MENGQIN ZHU1,2,3,4,#, TIANYI XU5,#, HAN ZHANG3,4, XIN FAN3,4, YULAN WANG6, JIAJIA ZHANG3,4, FEI YU1,2,3,4,* 1 Shanghai Clinical College, Anhui Medical University, Shanghai, 200040, China2 The Fifth Clinical Medical College, Anhui Medical University, Hefei, 230032, China3 Department of Nuclear Medicine, Shanghai Tenth People’s Hospital, Tongji University School of…

Continue Reading Characterization of prognosis and immune infiltration by a novel glutamine metabolism-related model in cutaneous melanoma

Continued CRC Research Informs Later-Line Disease Management

Tumor placement and response to neoadjuvant chemotherapy can help clarify and personalize later-line colorectal cancer (CRC) treatment approaches, according to Howard S. Hochster, MD, FACP, who also emphasized the potential benefits of the paradigm’s expansion to include VEGF inhibitors, such as fruquintinib (HMPL-013). “[Later lines of therapy are] still areas…

Continue Reading Continued CRC Research Informs Later-Line Disease Management

Sonodynamic amplification of cGAS-STING activation by cobalt-based nanoagonist against bone and metastatic tumor

Immunotherapy, a promising antitumor modality consisting of a series of therapeutic strategies that mobilize the endogenous immune system to execute an antitumor response, has drawn substantial attention in recent years [1]. However, hyporesponsiveness among patients, which is attributed to a category of immunosuppressive ‘cold’ tumors, hinders the further clinical application…

Continue Reading Sonodynamic amplification of cGAS-STING activation by cobalt-based nanoagonist against bone and metastatic tumor

Combination of PARP inhibitor and CDK4/6 inhibitor modulates cGAS/STING-dependent therapy-induced senescence and provides “one-two punch” opportunity with anti-PD-L1 therapy in colorectal cancer

doi: 10.1111/cas.15961. Online ahead of print. Tao Wang  1   2 , Weizhen Liu  1 , Qian Shen  3 , Ruikang Tao  4 , Chengguo Li  1 , Qian Shen  1 , Yao Lin  1 , Yongzhou Huang  1 , Lei Yang  1 , Gengchen Xie  1 , Jie Bai  1 , Ruidong Li  1 , Lulu Wang  5 , Kaixiong Tao  1…

Continue Reading Combination of PARP inhibitor and CDK4/6 inhibitor modulates cGAS/STING-dependent therapy-induced senescence and provides “one-two punch” opportunity with anti-PD-L1 therapy in colorectal cancer

Focusing on the development of BsAbs in China, YZY Biopharma Announces Proposed Listing on the Main Board of SEHK

HONG KONG, Sept 13, 2023 – (ACN Newswire) – – Wuhan YZY Biopharma Co., Ltd. (“YZY Biopharma” or the “Company”, together with its subsidiaries, the “Group”, stock code: 2496.HK), a biotechnology company dedicated to developing bispecific antibody (BsAb)-based therapies to treat cancer-associated complications, cancer and age-related ophthalmologic diseases, announced the…

Continue Reading Focusing on the development of BsAbs in China, YZY Biopharma Announces Proposed Listing on the Main Board of SEHK

Improving the cytotoxic response of tumor-infiltrating lymphocytes towards advanced stage ovarian cancer with an oncolytic adenovirus expressing a human vIL-2 cytokine

Given the therapeutic impact that adoptive TILs transfer has had in the treatment of melanoma with cases of durable responses reported, and the demonstration of tumor-reactive lymphocytes infiltrating OvCa tumors, adoptive TILs transfer has been studied as an immunotherapeutic option for OvCa treatment [14, 36, 37]. In spite of improvements…

Continue Reading Improving the cytotoxic response of tumor-infiltrating lymphocytes towards advanced stage ovarian cancer with an oncolytic adenovirus expressing a human vIL-2 cytokine

New Technology for Mapping the Tumor Ecosystem Can Improve Cancer Research

Spatially resolved transcriptomics (SRT)technology can be used to promote individualized treatment and identify therapeutic targets for patients with cancer, according to a systemic review published in Advanced Science. SRT technology is able to map tumor cells’ distribution in space, provide information on the tumor’s relationship to the surrounding microenvironment, and…

Continue Reading New Technology for Mapping the Tumor Ecosystem Can Improve Cancer Research

Carcinotech drives cancer drug discovery

3D printing is capturing attention in the field of medicine of late. With the first 3D-printed drug being approved for the treatment of seizures, eight years ago, it was a consequential moment in healthcare, following which biotechs raced to step up personalized treatment. Now, with Chinese healthcare company Triastek turning…

Continue Reading Carcinotech drives cancer drug discovery

KRTA6A and FA2H Are Hub Genes Associated With Cgas-STING-related Immunogenic Cell Death in Lung Adenocarcinoma

Abstract Background/Aim: The immunogenic cell death (ICD) pathway plays a crucial prognostic role in lung adenocarcinoma (LUAD) therapy. The cyclic GMP–AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway is an upstream mechanism that drives ICD activation, but the interaction of hub genes remains unclear. The present study aimed to investigate…

Continue Reading KRTA6A and FA2H Are Hub Genes Associated With Cgas-STING-related Immunogenic Cell Death in Lung Adenocarcinoma

ncRNA | Free Full-Text | Non-Coding RNAs: Foes or Friends for Targeting Tumor Microenvironment

Received: 27 June 2023 / Revised: 17 August 2023 / Accepted: 22 August 2023 / Published: 28 August 2023 Round 1 Reviewer 1 Report This is a very comprehensive treatment of the topic of ncRNAs in cancer therapy. There is definitely a need for this work to be published but…

Continue Reading ncRNA | Free Full-Text | Non-Coding RNAs: Foes or Friends for Targeting Tumor Microenvironment

Postdoctoral Fellow – Humam Kadara Lab

Program DescriptionOur laboratory studies ecological mechanisms in early lung cancer development and response to immune-based treatment. We seek a talented and highly motivated postdoctoral fellow with a strong background in bioinformatics and passion in exploring the heterogeneity and evolution of tumor cells and tumor microenvironment (TME) using state-of-the-art single-cell and…

Continue Reading Postdoctoral Fellow – Humam Kadara Lab

Few lymphocytes detected by cell type deconvolution tools in lung adenocarcinoma

Few lymphocytes detected by cell type deconvolution tools in lung adenocarcinoma 1 Lung adenocarcinoma(LUAD) is a kind of solid tumor which is usually thought to originate from AT2 cells in aveolar epithelium. Recently I tried BayesPrism, SCDC and MuSiC to deconvolute LUAD bulk RNA seq data with single cell from…

Continue Reading Few lymphocytes detected by cell type deconvolution tools in lung adenocarcinoma

PROs Represent a Vital Aspect in Design of GI Cancer Clinical Trials

Incorporating patient-reported outcomes (PROs) as a measurement of success in clinical trials, supplementary to measuring adverse effects (AEs), continues to be an area of great interest, across the gastrointestinal (GI) cancer landscape, and as clinical trials continue to evolve, it remains important to make sure that the patient’s voice is…

Continue Reading PROs Represent a Vital Aspect in Design of GI Cancer Clinical Trials

Strategies to therapeutically modulate cytokine action

Cohen, S., Bigazzi, P. E. & Yoshida, T. Commentary. Similarities of T cell function in cell-mediated immunity and antibody production. Cell Immunol. 12, 150–159 (1974). Article  CAS  PubMed  Google Scholar  Keegan, A. D. & Leonard, W. J. in Paul’s Fundamental Immunology 8th edn, ch. 9 (eds Flajnik, M. F., Singh,…

Continue Reading Strategies to therapeutically modulate cytokine action

DNA sensing in cancer: Pro-tumour and anti-tumour functions of cGAS-STING signalling

. 2023 Aug 3;EBC20220241. doi: 10.1042/EBC20220241. Online ahead of print. Affiliations Expand Affiliation 1 Division of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Lancaster, U.K. Item in Clipboard Otto P G Wheeler et al. Essays Biochem. 2023. Show details Display options Display options Format AbstractPubMedPMID . 2023…

Continue Reading DNA sensing in cancer: Pro-tumour and anti-tumour functions of cGAS-STING signalling

Exelixis Principal Bioinformatics Scientist (Cancer Biology) in Alameda, CA | 857300913

SUMMARY/JOB PURPOSE: The Principal Bioinformatics Scientist with an emphasis on cancer biology is a highly motivated interdisciplinary and data scientist who has signficant experience in conducting computational analyses of clinical and multi-omics data sets to identify potential mechanisms of drug action and resistance and relationships between potential targets and cancer…

Continue Reading Exelixis Principal Bioinformatics Scientist (Cancer Biology) in Alameda, CA | 857300913

Highlights from the 2023 Single-Cell and AI in Medicine Symposium

By Randall C. Willis with review and comments from Fabrice Chouraqui, Laurens Kruidenier, Chad Nusbaum, Diogo Camacho  August 2, 2023 | “Technology and computation are revolutionizing the way we are creating and developing new drugs,” Cellarity CEO Fabrice Chouraqui announced to open the Second Single-Cell and AI in Medicine Symposium…

Continue Reading Highlights from the 2023 Single-Cell and AI in Medicine Symposium

BioAtla Reports Second Quarter 2023 Financial Results and

Achieved first patient in (FPI) and continuing to enroll CAB-AXL BA3011 in a Phase 2 potentially registrational study in Undifferentiated Pleomorphic Sarcoma (UPS) Submitted Food & Drug Administration (FDA) meeting request for potentially registrational study of BA3011 in non-small cell lung cancer (NSCLC) study; FDA feedback and initiation of study…

Continue Reading BioAtla Reports Second Quarter 2023 Financial Results and

Chemically programmed STING-activating nano-liposomal vesicles improve anticancer immunity

Rational design of STING-activating pro-drugs for liposomal formulation A recently discovered non-nucleotide STING agonist, MSA-2, was selected to test the validity of our drug design. To facilitate the liposomal formulation of MSA-2, four synthetic MSA-2 derivatives (compounds 1–4) were initially constructed via ester bonds using MP-typed alkanols of varying lengths…

Continue Reading Chemically programmed STING-activating nano-liposomal vesicles improve anticancer immunity

ggplot2 – Plotting survival curves from two different models on the same graph, in R

I am working with two different binary classification models, each having a different number of test samples (there are some mutual samples). The prediction scores from these models are used to split the samples into two groups – group 0 and group 1 – using the median prediction score as…

Continue Reading ggplot2 – Plotting survival curves from two different models on the same graph, in R

Treatment of adults with relapsed or refractory DLBCL

Introduction Diffuse Large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma (NHL), accounting for 31% of NHL cases in Western countries.1,2 The median age at presentation is 66, and 5-year survival rates decrease by age from 78% for those younger than 55 years to 54% for those over 65…

Continue Reading Treatment of adults with relapsed or refractory DLBCL

The effective treatment of malignant melanoma.

Plain-Language Summary Malignant melanoma (MM) is the most lethal skin cancer. Recent studies have found that the invasion and metastasis of MM are related not only to MM gene mutation but also to the interaction between MM cells and the immune system and microenvironment. The application of RNAi-based therapeutics to…

Continue Reading The effective treatment of malignant melanoma.

Cationic platinum-based drugs as STING agonists for enhanced chemoimmunotherapy polymers

*For medical professionals to read and reference only STING agonists have made great progress in the diagnosis and treatment of tumor immunity . However, its inherent instability and low bioavailability limit its wide application. Based on this, Yu Yingjie’s team at Beijing University of Chemical Technology introduced a reduction-sensitive polymer…

Continue Reading Cationic platinum-based drugs as STING agonists for enhanced chemoimmunotherapy polymers

Cancers | Free Full-Text | A Novel Bispecific Antibody for EpCAM-Directed Inhibition of the CD73/Adenosine Immune Checkpoint in Ovarian Cancer

1. Introduction Typically, tumors in patients with ovarian cancer (OC) are often diagnosed at an advanced stage [1]. Currently, cytoreductive therapy with platinum-based chemotherapy is the mainstay of disease management, to which the majority of patients with OC initially respond. Unfortunately, 70% of these patients eventually develop refractory recurrences [2]….

Continue Reading Cancers | Free Full-Text | A Novel Bispecific Antibody for EpCAM-Directed Inhibition of the CD73/Adenosine Immune Checkpoint in Ovarian Cancer

TME Pharma provides positive glioblastoma trial results

TME Pharma N.V. has announced a positive clinical update on the best response to therapy, reporting one patient achieving complete response in the GLORIA expansion arm evaluating NOX-A12, TME Pharma’s CXCL12 inhibitor, in combination with standard of care radiotherapy and anti-VEGF, bevacizumab, in first-line glioblastoma. TME Pharma is a biotechnology…

Continue Reading TME Pharma provides positive glioblastoma trial results

Lymph Node Fibroblasts May Suppress T-Cell Function in DLBCL

The immunosuppressive role of fibroblastic reticular cells (FRCs) in diffuse large B-cell lymphoma (DLBCL) is detailed in new research published in The Journal of Clinical Investigation. According to the study’s authors, these findings could have implications for disease pathogenesis and for optimizing immunotherapy in patients with DLBCL. The disease has…

Continue Reading Lymph Node Fibroblasts May Suppress T-Cell Function in DLBCL

An integrative bioinformatics investigation and experimental validation of chromobox family in diffuse large B-cell lymphoma | BMC Cancer

The mRNA expression levels of CBX family in DLBCL patients To explore the expression differences of the CBX family in DLBCL patients, the GEPIA database was used (Fig. 2). Based on the data obtained from GEPIA, the expression levels of CBX1, CBX2, CBX3, CBX5, CBX6, and CBX8 in DLBCL were higher…

Continue Reading An integrative bioinformatics investigation and experimental validation of chromobox family in diffuse large B-cell lymphoma | BMC Cancer

New Classification Approach May Identify Early Clinical Failure in DLBCL

A recent preprint in medRxiv has demonstrated a novel integrative computation-based classification approach capable of effectively identifying multiomic signatures of early clinical failure in patients with diffuse large B-cell lymphoma (DLBCL). The study found that the proposed DLBCL classifier signature was associated with event-free survival within 24 months of diagnosis (EFS24), metabolic reprogramming, and…

Continue Reading New Classification Approach May Identify Early Clinical Failure in DLBCL

Targeting cGAS/STING signaling-mediated myeloid immune cell dysfunction in TIME

Review doi: 10.1186/s12929-023-00942-2. Affiliations Expand Affiliations 1 Department of Interdisciplinary Oncology, Stanley S. Scott Cancer Center, School of Medicine, Louisiana State University Health Science Center (LSUHSC), 1700 Tulane Avenue, New Orleans, LA, 70012, USA. vkuma2@lsuhsc.edu. 2 Department of Interdisciplinary Oncology, Stanley S. Scott Cancer Center, School of Medicine, Louisiana State…

Continue Reading Targeting cGAS/STING signaling-mediated myeloid immune cell dysfunction in TIME

Exosomal circRNA: emerging insights into cancer progression and clinical application potential | Journal of Hematology & Oncology

He G, Peng X, Wei S, Yang S, Li X, Huang M, et al. Exosomes in the hypoxic TME: from release, uptake and biofunctions to clinical applications. Mol Cancer. 2022;21:19. Article  PubMed  PubMed Central  Google Scholar  Downs-Canner SM, Meier J, Vincent BG, Serody JS. B cell function in the tumor…

Continue Reading Exosomal circRNA: emerging insights into cancer progression and clinical application potential | Journal of Hematology & Oncology

Integrated bioinformatics and wet-lab analysis revealed cell adhesion prominent genes CDC42, TAGLN and GSN as prognostic biomarkers in colonic-polyp lesions

Clinicopathological characteristics of patients with pre-cancerous lesions Clinicopathological features of the 20 included patients with colon polyps were extracted from their files and presented at the beginning of the survey. All resected samples were categorized into high-risk and low-risk polyps based on reported pathological feature of the samples. The mean…

Continue Reading Integrated bioinformatics and wet-lab analysis revealed cell adhesion prominent genes CDC42, TAGLN and GSN as prognostic biomarkers in colonic-polyp lesions

The Basics of the Tumor Microenvironment

Stay up to date on the latest science with Brush Up Summaries. What Is the Tumor Microenvironment?  The tumor microenvironment (TME) is a local area created and dominated by a tumor that contains different cell types and chemical signals. It catalyzes tumor growth and can contribute to cancer cells acquiring…

Continue Reading The Basics of the Tumor Microenvironment

ENPP1 Immunobiology as a Therapeutic Target | Clinical Cancer Research

Figure 1. ATP–Ado extracellular metabolism and elicited signaling through adenosinergic receptors. A, Canonical and noncanonical extracellular receptors contributing to the hydrolysis of ATP and other metabolites. In the TME, two different yet partially overlapping pathways mediate the hydrolysis of ATP to adenosine (Ado). In the noncanonical pathway, Ado can be…

Continue Reading ENPP1 Immunobiology as a Therapeutic Target | Clinical Cancer Research

Multiomic Analysis Identifies a High-Risk Metabolic and TME Depleted Signature that Predicts Early Clinical Failure in DLBCL

Abstract PURPOSE 60-70% of newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients avoid events within 24 months of diagnosis (EFS24) and the remainder have poor outcomes. Recent genetic and molecular classification of DLBCL has advanced our knowledge of disease biology, yet were not designed to predict early events and guide…

Continue Reading Multiomic Analysis Identifies a High-Risk Metabolic and TME Depleted Signature that Predicts Early Clinical Failure in DLBCL

Advances in the Understanding of DLBCL Immunology Could Spark Novel Therapies

The development of new therapies and new technologies is leading to a better understanding of the immunology of diffuse large B-cell lymphoma (DLBCL), according to a new review. The article, published in the journal Cancers, outlines the latest insights and their implications for patient care. Corresponding author Taishi Takahara, MD,…

Continue Reading Advances in the Understanding of DLBCL Immunology Could Spark Novel Therapies

Robust IL-2-dependent antitumor immunotherapy requires targeting the high-affinity IL-2R on tumor-specific CD8+ T cells

Introduction Interleukin (IL)-2 was the first Food and Drug Administration approved immunotherapy for use in patients with metastatic melanoma and renal cell carcinoma.1 2 However, the use of recombinant IL-2 (Proleukin/aldesleukin) has been problematic due to low response rates, off-target effects, and severe dose-dependent toxicities. Due to its potent T-cell…

Continue Reading Robust IL-2-dependent antitumor immunotherapy requires targeting the high-affinity IL-2R on tumor-specific CD8+ T cells

Roles of circRNA dysregulation in esophageal squamous cell carcinoma tumor microenvironment

1Medical Research Center, the Second Affiliated Hospital of Zhengzhou University, China 2Department of Reproductive Medicine, Second Affiliated Hospital of Zhengzhou University, China 3Department of Clinical Laboratory, Second Affiliated Hospital of Zhengzhou University, China The final, formatted version of the article will be…

Continue Reading Roles of circRNA dysregulation in esophageal squamous cell carcinoma tumor microenvironment

[Nature Sub-Journal] National Taiwan University Chen Ruihua and others have discovered new targets for anti-tumor immunotherapy

Introduction: Activation of tumor-intrinsic innate immunity has been a major strategy for improving cancer immunotherapy. Previously, we reported an autophagy-promoting function of the deubiquitinating enzyme TRABID. Today, we identify a critical role for TRABID in suppressing antitumor immunity. On May 26, researchers from National Taiwan University published the paper “TRABID…

Continue Reading [Nature Sub-Journal] National Taiwan University Chen Ruihua and others have discovered new targets for anti-tumor immunotherapy

JCI – Tumor-activated lymph node fibroblasts suppress T cell function in diffuse large B cell lymphoma

Recent transcriptomic-based analysis of diffuse large B cell lymphoma (DLBCL) has highlighted the clinical relevance of lymph node (LN) fibroblast and tumor-infiltrating lymphocyte (TIL) signatures within the tumor microenvironment (TME). However, the immunomodulatory role of fibroblasts in lymphoma remains unclear. Here, by studying human and mouse DLBCL-LNs, we identify the…

Continue Reading JCI – Tumor-activated lymph node fibroblasts suppress T cell function in diffuse large B cell lymphoma

Identification and validation of TME-related signatures to predict prognosis and response to anti-tumor therapies in skin cutaneous melanoma

The tumor microenvironment (TME) dynamically regulates cancer progression and affects clinical outcomes. This study aimed to identify molecular subtypes and construct a prognostic risk model based on TME-related signatures in skin cutaneous melanoma (SKCM) patients. We categorized SKCM patients based on transcriptome data of SKCM from The Cancer Genome Atlas…

Continue Reading Identification and validation of TME-related signatures to predict prognosis and response to anti-tumor therapies in skin cutaneous melanoma

BioAtla Reports First Quarter 2023 Financial Results and Highlights Recent Progress

BioAtla, Inc. Advancing CAB-AXL BA3011 in ongoing sarcoma Phase 2 studies including a potentially registrational study in Undifferentiated Pleomorphic Sarcoma (UPS); expect Leiomyosarcoma (LMS) cohort readout in 2H23 On track for submitting a meeting request to the Food & Drug Administration (FDA) for the potentially registrational BA3011 Phase 2, part…

Continue Reading BioAtla Reports First Quarter 2023 Financial Results and Highlights Recent Progress

BioAtla Reports First Quarter 2023 Financial Results and

Advancing CAB-AXL BA3011 in ongoing sarcoma Phase 2 studies including a potentially registrational study in Undifferentiated Pleomorphic Sarcoma (UPS); expect Leiomyosarcoma (LMS) cohort readout in 2H23 On track for submitting a meeting request to the Food & Drug Administration (FDA) for the potentially registrational BA3011 Phase 2, part 2 non-small…

Continue Reading BioAtla Reports First Quarter 2023 Financial Results and

Comprehensive prediction of immune microenvironment and hot and cold tumor differentiation in cutaneous melanoma based on necroptosis-related lncRNA

Identify necroptosis-related lncRNAs in SKCM There are 386 necroptosis-related lncRNAs identified from the data of TCGA and GTEx, as the standard is the coefficients > 0.4 and P < 0.001. After that, flowing the differential expression analysis, 87 necroptosis-related lncRNAs were found to display significantly differential expression with the screen value as |logFC…

Continue Reading Comprehensive prediction of immune microenvironment and hot and cold tumor differentiation in cutaneous melanoma based on necroptosis-related lncRNA

Cell therapy data shows killing of pancreatic cancer tumoroids

LIfT BioSciences has revealed preclinical data demonstrating that its immunomodulatory alpha neutrophil product (IMAN) showed potent killing of pancreatic cancer tumoroids.  The tumoroid originated from a patient with pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer. The patient was unresponsive to conventional chemotherapy treatment with Abraxane (nab-paclitaxel),…

Continue Reading Cell therapy data shows killing of pancreatic cancer tumoroids

Breast implant associated EBV-positive Diffuse Large B-cell lymphoma: an underrecognized entity? | Diagnostic Pathology

We report two cases of EBV + DLBCL arising in relation to breast implants. Both lymphomas contained CD30 + large atypical cells, a typical feature of BIA-ALCL, the most common lymphoma type, seen in association with breast implants. BIA-ALCL has recently been recognized a separate entity by the WHO HAEM5 and the ICC, whereas…

Continue Reading Breast implant associated EBV-positive Diffuse Large B-cell lymphoma: an underrecognized entity? | Diagnostic Pathology

Analysis of differential gene immune infiltration and clinical characteristics of skin cutaneous melanoma based on systems biology and drug repositioning methods to identify drug candidates for skin cutaneous melanoma

Skin cutaneous melanoma (SKCM) has a low early detection rate and a high mortality rate. There are many problems such as side effects and drug resistance in existing therapeutic drugs. Current studies have confirmed that SKCM pathogenesis-related genes promote the invasion and metastasis of cutaneous melanoma, but their roles in…

Continue Reading Analysis of differential gene immune infiltration and clinical characteristics of skin cutaneous melanoma based on systems biology and drug repositioning methods to identify drug candidates for skin cutaneous melanoma

The prognostic value of hedgehog signaling in bladder cancer by integrated bioinformatics

HhS activation is a marker of poor prognosis in BLCA patients First, HhS scores were calculated and its expression characteristics were analyzed for patients in the TGCA-BLCA cohort. The results showed that HhS was overactivated in patients with higher stage and older age (Fig. 2A, B). And there is no significant…

Continue Reading The prognostic value of hedgehog signaling in bladder cancer by integrated bioinformatics

New nanomedicine can suppress tumors by turning ‘cold’ tumors into ‘hot’ ones

*For medical professionals to read and reference only Recently, the team of Dean Li Jie of the Oncology Department of Guang’anmen Hospital, China Academy of Chinese Medical Sciences , based on the immune effect of papaya saponin I, developed a new nano-drug that can achieve efficient tumor suppression by converting…

Continue Reading New nanomedicine can suppress tumors by turning ‘cold’ tumors into ‘hot’ ones

Collaborative breakthrough for rectal cancer patients

The preliminary results from a whole genome minimal residual disease (MRD) test were evaluated in 31 patients with locally advanced rectal cancer (LARC). C2i Genomics and Memorial Sloan Kettering performed a collaborative study as part of the Organ Preservation for Rectal Adenocarcinoma (OPRA) trial. The test was evaluated for the…

Continue Reading Collaborative breakthrough for rectal cancer patients

A pan-cancer analysis of DDR1 in prognostic signature and tumor immunity, drug resistance

Differential expression of DDR1 between tumor and normal tissue samples To better understand DDR1 expression levels in various cancer types, we first performed a pan-cancer analysis of 33 cancers in the TCGA database. Excluding cancers without corresponding normal samples, significant differences in DDR1 expression were found between tumor and normal…

Continue Reading A pan-cancer analysis of DDR1 in prognostic signature and tumor immunity, drug resistance

ORIEN Researchers to Present Key Findings Utilizing M2GEN’s Avatar Data at AACR Annual Meeting

Presentations highlight the utility of using real-world data to drive precision medicine forward TAMPA, Fla., April 7, 2023 /PRNewswire/ — M2Gen, an oncology-focused health informatics solutions company, today announced its participation as a presenter, exhibitor, and research partner at the American Association for Cancer Research (AACR) Annual Meeting…

Continue Reading ORIEN Researchers to Present Key Findings Utilizing M2GEN’s Avatar Data at AACR Annual Meeting

BioAtla Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Progress

– Cleared dose-limiting toxicity (DLT) observation period with more frequent, dose-intensive regimen of CAB-AXL BA3011; anticipated leiomyosarcoma (LMS) cohort readout in 2H23 – Initiated the potentially registrational Phase 2, part 2 BA3011 Undifferentiated Pleomorphic Sarcoma (UPS) study in 1H23 including more frequent, dose-intensive regimens – On track for submitting a…

Continue Reading BioAtla Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Progress

G9a promotes immune suppression by targeting the Fbxw7/Notch pathway in glioma stem cells

Aim: Immunotherapy for glioblastoma multiforme (GBM) is limited because of a strongly immunosuppressive tumor microenvironment (TME). Remodeling the immune TME is an effective strategy to eliminate GBM immunotherapy resistance. Glioma stem cells (GSCs) are inherently resistant to chemotherapy and radiotherapy and involved in immune evasion mechanism. This study aimed to…

Continue Reading G9a promotes immune suppression by targeting the Fbxw7/Notch pathway in glioma stem cells

LIfT BioSciences hails breakthrough for curing solid tumors

LIfT BioSciences has announced what it says are exciting preclinical data demonstrating that its immunomodulatory alpha neutrophil product (IMANp) possesses both cytotoxic and immunomodulatory functionalities. The company said these are commonly cited by medical professionals as being critical for potentially curing solid tumors in patients. LIfT said this involved learning from…

Continue Reading LIfT BioSciences hails breakthrough for curing solid tumors

Why are colon cancer rates in young people rising?

In a recent perspective article published in the journal Science, researchers at the Young-Onset Colorectal Cancer Center of Dana-Farber Cancer Institute emphasized that a better understanding of the etiology of early-onset colorectal cancer (EOCRC) is crucial to managing its increasing incidence worldwide. So, they identified five critical areas for investigating…

Continue Reading Why are colon cancer rates in young people rising?

Purple Biotech sees positive results from cancer study

Purple Biotech Ltd. has released new results from exploratory analyses conducted as part of a phase 1 dose escalation study that assessed the safety and tolerability of nivolumab and CM24, which is a monoclonal antibody.  Purple Biotech is a clinical-stage company developing first-in-class therapies that harness the tumor microenvironment (TME)…

Continue Reading Purple Biotech sees positive results from cancer study

FDA Okays IND Application of BA3182 for Advanced Adenocarcinoma

The FDA has cleared an investigational new drug (IND) application to evaluate BA3182 for the treatment of patients with advanced adenocarcinoma, according to BioAtla, Inc. As a result of the IND, the company plans to initiate and advance a phase 1 dose-escalation and dose-expansion clinical trial in 2023, which will…

Continue Reading FDA Okays IND Application of BA3182 for Advanced Adenocarcinoma

BioAtla Announces FDA Clearance of Investigational New Drug

Following the IND clearance, the Company is advancing into a Phase 1 clinical study Potentially addressing most common subtypes of adenocarcinoma including colon, lung, breast, pancreas, and prostate SAN DIEGO, Feb. 23, 2023 (GLOBE NEWSWIRE) — BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of…

Continue Reading BioAtla Announces FDA Clearance of Investigational New Drug

ggplot2 – Comparison between two different species with different gene, tissue names and number of tissues in R

I want to create 2,3 heatmaps or barcharts side by side for every gene ortholog between two or three different species in R. The problem is that my data are unbalanced, meaning I have gene names which are different between the two species (cat1_gene – mat1_gene) and tissues which are…

Continue Reading ggplot2 – Comparison between two different species with different gene, tissue names and number of tissues in R

Bioinformatics construction and experimental validation of a cuproptosis-related lncRNA prognostic model in lung adenocarcinoma for immunotherapy response prediction

Data collection and processing The RNA-sequencing data, clinical information and simple nucleotide variation of LUAD patients were retrieved from TCGA database (portal.gdc.cancer.gov/, accessed April 8, 2022). Nineteen cuproptosis-related genes (CRG) were mainly collected from previous study, including LIPT1, GLS, NFE2L2, NLRP3, LIAS, ATP7B, ATP7A, SLC31A1, FDX1, LIPT2, DLD, DLAT, PDHA1,…

Continue Reading Bioinformatics construction and experimental validation of a cuproptosis-related lncRNA prognostic model in lung adenocarcinoma for immunotherapy response prediction

Comprehensive Analysis of NPSR1-AS1 as a Novel Diagnostic and Prognostic Biomarker Involved in Immune Infiltrates in Lung Adenocarcinoma

The incidence of lung adenocarcinoma (LUAD), the most common subtype of lung cancer, continues to make lung cancer the largest cause of cancer-related deaths worldwide. Long noncoding RNAs (lncRNAs) have been shown to have a significant role in both the onset and progression of lung cancer. In this study, we…

Continue Reading Comprehensive Analysis of NPSR1-AS1 as a Novel Diagnostic and Prognostic Biomarker Involved in Immune Infiltrates in Lung Adenocarcinoma

It is time to start the renaissance of aptamers

Who here has heard of an aptamer? Most people by now would have heard of RNA and are likely to have been the recipient of a strand or two thanks to COVID vaccines. Macugen was the first RNA biotherapeutic approved by the US Food and Drug Administration (FDA) in 2004,…

Continue Reading It is time to start the renaissance of aptamers

Subtype and cell type specific expression of lncRNAs provide insight into breast cancer

lncRNA expression according to breast cancer clinicopathological subtypes To identify lncRNAs expressed by specific breast cancer subtypes or associated with clinicopathological features, we analyzed RNA-sequencing data from two large independent breast cancer cohorts: SCAN-B (n = 3455)17 and TCGA-BRCA (n = 1095). We focused on lncRNAs annotated in the Ensembl18 v93 non-coding reference transcriptome…

Continue Reading Subtype and cell type specific expression of lncRNAs provide insight into breast cancer

DataSheet1_Single-Cell RNA-Seq and Bulk RNA-Seq Reveal Intratumoral Heterogeneity and Tumor Microenvironment Characteristics in Diffuse Large B-Cell Lymphoma.docx

Background: Diffuse large B-cell lymphoma (DLBCL) is the most common histologic subtype of non-Hodgkin’s lymphoma (NHL) with highly heterogeneous genetic and phenotypic features. Therefore, a comprehensive understanding of cellular diversity and intratumoral heterogeneity is essential to elucidate the mechanisms driving DLBCL progression and to develop new therapeutic approaches. Methods: We…

Continue Reading DataSheet1_Single-Cell RNA-Seq and Bulk RNA-Seq Reveal Intratumoral Heterogeneity and Tumor Microenvironment Characteristics in Diffuse Large B-Cell Lymphoma.docx

Glioblastoma scRNAseq Shows Treatment-induced, Immune-dependent Rise In Mesenchymal Cancer Cells, and Structural Variants in Distal Neural Stem Cells

This article was originally published here Neuro Oncol. 2022 Apr 13:noac085. doi: 10.1093/neuonc/noac085. Online ahead of print. ABSTRACT BACKGROUND: Glioblastoma is a treatment-resistant brain cancer. Its hierarchical cellular nature and its tumour microenvironment (TME) before, during, and after treatments remain unresolved. METHODS: Here, we used single-cell RNA-sequencing to analyze new…

Continue Reading Glioblastoma scRNAseq Shows Treatment-induced, Immune-dependent Rise In Mesenchymal Cancer Cells, and Structural Variants in Distal Neural Stem Cells

Identification of lipid metabolism-associated gene signature

Background Female breast cancer has surpassed lung cancer as the most commonly diagnosed cancer. Despite the dramatic improvement in breast cancer prognosis due to recent therapeutic advances, such as more effective adjuvant and neo-adjuvant chemotherapies, together with more radical and safer surgery, advances in early diagnosis and treatment over the…

Continue Reading Identification of lipid metabolism-associated gene signature

IRE combined with toripalimab versus IRE alone for LAPC

Introduction Pancreatic ductal adenocarcinoma (PDAC) is a lethal gastrointestinal disease with increasing morbidity, which also has a growing impact on cancer-specific mortality worldwide.1 Nearly 40% of all PDAC cases are localized to the pancreas and characterized with the involvement of major vascular structures, leading to unresectable disease without metastases detected…

Continue Reading IRE combined with toripalimab versus IRE alone for LAPC